Ursolic Acid Conjugates: A New Frontier in Anticancer Drug Development

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Ursolic acid (UA) is a natural compound with potential anticancer properties.
• Developing novel UA derivatives can enhance efficacy and selectivity against various cancers.
• Targeting aggressive and drug-resistant cancer types remains a significant challenge in oncology.

Purpose of the Study:

• To synthesize novel ursolic acid conjugates using molecular hybridization.
• To evaluate the in vitro antiproliferative and cytotoxic activities of these conjugates against cancer cell lines.
• To investigate the selectivity and mechanisms of action of the most potent UA conjugates.

Main Methods:

• Synthesis of UA conjugates at C-3 and C-28 positions via optimized protocols.
• In vitro testing of antiproliferative and cytotoxic effects on bladder (T24, 5637) and breast (MDA-MB 231, MCF-12A) cancer cell lines.
• Assessment of compound selectivity towards cancer cells versus normal epithelial cells.

Main Results:

• Successfully synthesized UA conjugates with good yields.
• Several conjugates exhibited enhanced antiproliferative activity against triple-negative breast cancer (TNBC) and bladder cancer cell lines compared to parent UA.
• Compounds 18c and 18d showed significant antiproliferative and cytotoxic effects.
• Compound 18d displayed exceptional selectivity for cancer cells and potent cytotoxicity against chemotherapy-resistant cells (e.g., Gemcitabine-resistant).

Conclusions:

• Novel UA conjugates possess significant anticancer potential, outperforming the parent compound.
• Compound 18d represents a promising lead candidate due to its high selectivity and efficacy against resistant cancer cells.
• The observed mechanisms, including cytotoxic autophagy and programmed cell death, suggest potential for novel combination therapies.